Navigation Links
Novel antiviral technology inhibits RSV infection in mice

A novel antiviral treatment combining nanoparticle and gene silencing technologies thwarts attacks of respiratory syncytial virus (RSV) -- a virus associated with severe bronchitis and asthma, an animal study by University of South Florida researchers found. The study was reported in the January 2005 issue of the journal Nature Medicine. RSV infects lung cells and can be life-threatening in very young children, the elderly and those with compromised immune systems. No vaccine or widespread antiviral treatment is available for the infection.

Researchers at USF's Joy McCann Culverhouse Airway Disease Research Center, working with scientists from the Moffitt Cancer Center and TransGenex Nanobiotech Inc., used a revolutionary new technology known as RNA interference, or gene silencing, to knock out one of the key proteins needed for RSV to multiply in the lungs. The virus harnesses this protein, known as NS1, to block the body's own antiviral response, which would normally kill RSV before it could gain a foothold. "This is an exciting advance in the fight against respiratory syncytial virus infection," said Shyam S. Mohapatra, PhD, principal investigator of the study and director of basic research at the USF Division of Allergy and Immunology. "We found that RNA interference targeting a virus's NS1 gene can be administered in the form of a nasal drop or spray. The treatment keeps the host's natural antiviral shield intact and attenuates virus reproduction, providing substantial protection from severe infections over days to weeks." Dr. Mohapatra and his team developed nose drops containing vectors capable of producing small fragments of RNA (siRNA). These fragments were encapsulated within chitosan nanoparticles -- miniscule naturally-occurring, biodegradable particles that stick to mucous-producing cells lining the lungs. The RNA produced is specifically designed to suppress the protein NS1. Without NS1, the host antiviral defense remains intact and the virus ca nnot reproduce. Mice treated intranasally with the gene-silencing nanoparticles, before and after infection with RSV, showed significantly lower levels of virus in the lung and less airway inflammation and hyper-reactivity than untreated mice.
'"/>

Source:Eurekalert


Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Novel technology detects human DNA mutations
3. Novel Enzyme Shows Potential As An Anti-HIV Target
4. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
5. Discovery Could Lead To Novel Approaches In HIV Treatment
6. Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells
7. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
8. Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma
9. Novel live reporting system to track cells
10. Field of beams - Novel system uses polarized light pulses to reveal crop health
11. Novel compounds show promise as safer, more potent insecticides

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
(Date:3/18/2016)... LONDON , March 18, 2016 ... Established Suppliers of Biometrics, ICT, Manned & Unmanned Vehicles, Physical ... & security companies in the border security market and ... and Europe has led ... your companies improved success. --> defence & ...
(Date:3/15/2016)... 2016 Yissum Research Development Company of ... of the Hebrew University, announced today the formation of ... of various human biological indicators. Neteera Technologies has completed ... private investors. ... of electromagnetic emissions from sweat ducts, enables reliable and ...
Breaking Biology News(10 mins):
(Date:4/27/2016)... ... 27, 2016 , ... The Pittcon Organizing Committee is pleased to announce that ... volunteer member of Committee since 1987. Since then, he has served in a number ... was chairman for both the program and exposition committees. In his professional career, Dr. ...
(Date:4/27/2016)... ... April 27, 2016 , ... ... to announce the appointment of John Tilton as Chief Commercial Officer.  Mr. Tilton ... one of the founding commercial leaders responsible for the commercialization of multiple orphan ...
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... Global ... the GSCG Advisory Board. Ross is the founder of GSCG affiliate Kimera Labs in ... Miami, where he studied hematopoietic stem cell transplantation for hematologic disorders and the suppression ...
(Date:4/26/2016)... Calif. (PRWEB) , ... April 27, 2016 , ... ... office of Lewis Roca Rothgerber Christie LLP as an associate in the firm’s ... U.S. and international electrical, mechanical and electromechanical patent applications. He has an electrical ...
Breaking Biology Technology: